GMRA INVESTIGATION
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $14,438 | 1 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $14,438 | 1 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A POSPECTIVE MULTICENTER COHORT STUDY EVALUATING THE LONG TERM RETENTION OF GADOLINIUM IN HUMAN BONE AND SKIN AFTER THE RETROSPECTIVE ADMINISTRATION OF MULTIHANCE OR PROHANCE IN COMPARISON WITH A CONTROL GROUP RECEIVING NO EXPOSURE TO GADOLINIUM | BRACCO DIAGNOSTICS INC. | $14,438 | 0 |
Top Doctors Receiving Payments for GMRA INVESTIGATION
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Boston, MA | $14,438 | 1 |
Manufacturing Companies
- BRACCO DIAGNOSTICS INC. $14,438
Product Information
- Type Drug
- Total Payments $14,438
- Total Doctors 0
- Transactions 1
About GMRA INVESTIGATION
GMRA INVESTIGATION is a drug associated with $14,438 in payments to 0 healthcare providers, recorded across 1 transactions in the CMS Open Payments database. The primary manufacturer is BRACCO DIAGNOSTICS INC..
Payment data is available from 2017 to 2017. In 2017, $14,438 was paid across 1 transactions to 0 doctors.
The most common payment nature for GMRA INVESTIGATION is "Unspecified" ($14,438, 100.0% of total).
GMRA INVESTIGATION is associated with 1 research study, including "A POSPECTIVE MULTICENTER COHORT STUDY EVALUATING THE LONG TERM RETENTION OF GADOLINIUM IN HUMAN BONE AND SKIN AFTER THE RETROSPECTIVE ADMINISTRATION OF MULTIHANCE OR PROHANCE IN COMPARISON WITH A CONTROL GROUP RECEIVING NO EXPOSURE TO GADOLINIUM" ($14,438).